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OBJECTIVES We investigated whether autologous transplantation of skeletal myoblasts (MB) transferred
with cardiotrophin-1 (CT-1) gene could retard the transition to heart failure (HF) in Dahl
salt-sensitive (DS) hypertensive rats.
BACKGROUND Although MB is a therapeutic candidate for chronic HF, little is known about the efficiency
of this strategy when applied in nonischemic HF. Cardiotrophin-1 has potent hypertrophic
and survival effects on cardiac myocytes. We hypothesized that transplantation of CT-1–
expressing myoblasts could provide cardioprotective effects against ventricular remodeling in
DS hypertensive rats.
METHODS The DS rats were fed a high salt diet for 6 weeks and developed left ventricular (LV)
hypertrophy at 11 weeks. At this stage, animals underwent MB to the myocardium with
skeletal myoblasts transferred with CT-1 gene using retrovirus (transplantation of CT-1–
expressing myoblasts [MB  CT], n  31) or myoblasts alone (MB, n  31). The sham
group rats were injected with phosphate-buffered saline (n  24).
RESULTS At 17 weeks, MB and MB  CT groups showed a significant alleviation of LV dilation and
contractile dysfunction compared with the sham group. The degree of alleviation was
significantly greater in the MB  CT group than the MB group (LV end-diastolic
dimension: sham 7.06  0.14 mm, MB 6.51  0.16 mm, MB  CT 6.24  0.07 mm;
fractional shortening: sham 32.1  1.4%, MB 38.5  1.5%, MB  CT 43.2  0.8%).
Histological examination revealed that the myocyte size was 20% larger in the MB  CT
group at 17 weeks than in the age-matched sham group. Upregulation of renin-angiotensin
and endothelin systems during the transition to HF was attenuated by myoblast transplan-
tation, and this effect was enhanced in the MB  CT group.
CONCLUSIONS Transplantation of skeletal myoblasts combined with CT-1-gene transfer could be a useful
therapeutic strategy for HF. (J Am Coll Cardiol 2004;43:2337–47) © 2004 by the
American College of Cardiology Foundationt
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cespite medical and surgical advances, heart failure (HF) is
till a major cause of death. Because mature cardiac myo-
ytes cannot re-enter the cell cycle and the adult heart lacks
unctional repair mechanisms, myogenic cell transplantation
nto the damaged myocardium is a promising approach to
he treatment for end-stage HF (1). Recent experimental
tudies have demonstrated that intramyocardial skeletal
yoblast transplantation improves cardiac function after
yocardial infarction (2–5). Clinical trials with skeletal
yoblast transplantation are also on the way (6,7). How-
ver, little is known about the efficiency of this strategy
hen applied in global HF of nonischemic causes (8–10).
From the *Division of Cardiovascular and Respiratory Medicine, Department of
nternal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan; and
he †Department of Internal Medicine, Cardiovascular Division, Hyogo College of
edicine, Nishinomiya, Japan. Supported by grants-in-aid for the research from the
inistry of Health and Welfare of Japan (2002 to 2003) and from the Ministry of
ducation, Science, Sports, and Culture of Japan (2001 to 2002).
Manuscript received October 23, 2003; revised manuscript received December 30,003, accepted February 3, 2004.The Dahl salt-sensitive (DS) hypertensive rats undergo
he transition from compensatory hypertrophy to congestive
F (11). When they are fed a high salt diet after the age of
weeks, they develop systemic hypertension and concentric
eft ventricular (LV) hypertrophy at 11 weeks, followed by
arked LV dilation and contractile dysfunction at 15 to 20
eeks (11). Thus, they have been used as an animal model
or nonischemic hypertension-based HF. We investigated
hether autologous transplantation of skeletal myoblasts
MB) could retard the transition from compensatory hyper-
rophy to HF in DS hypertensive rats.
Skeletal myoblast transplantation is also useful as a tool
or cell-mediated gene therapy, providing sustained local
xpression of recombinant proteins in the heart (12,13).
ardiotrophin-1 (CT-1), a member of the interleukin-6
uperfamily, induces hypertrophy and prolongs survival of
ardiac myocytes in vitro (14–16). It has been reported that
T-1 expression in the myocardium is upregulated in
hronic HF (17,18). However, the pathophysiologic signif-
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CT-1–Myoblast Transplantation for HF June 16, 2004:2337–47cance of CT-1 in the transition from compensated to
ecompensated HF is not fully elucidated (18). We accord-
ngly analyzed the feasibility and efficiency of transplanting
keletal myoblasts that are transferred with CT-1 gene using
etrovirus in preserving cardiac function of DS hypertensive
ats. We hypothesized that this strategy could provide
ardioprotective effects against ventricular remodeling in
ombination with functional benefits of skeletal myoblast-
erived muscle.
ETHODS
nimal model and isolation of primary skeletal myoblasts.
ll animal experiments were performed in accordance with
he guidelines for animal experimentation at Kobe Univer-
ity Graduate School of Medicine. Male DS rats were
btained from Japan SLC Co. Ltd (Hamamatsu, Japan).
fter weaning, the rats were fed a low salt diet (0.3% NaCl)
ntil the age of six weeks; thereafter, a high salt diet (8%
aCl) was started. The myoblast culture process was per-
ormed according to the method reported previously (2). In
rief, skeletal muscles were harvested from hind limb
keletal muscle of DS rats, and then they were minced and
eeded on polystyrene plates. Tissue pieces were incubated
t 37°C for 48 h in Dulbecco’s Modified Eagle’s Medium
Sigma, St. Louis, Missouri) supplemented with 10% fetal
ovine serum (FBS), 100 g/ml streptomycin, and 500
g/ml penicillin (all from Sigma) to allow primary satellite
ell (myoblast) isolation. When cells began to migrate out of
issue, tissue pieces were removed. Myoblast growth densi-
ies were maintained at 70% to avoid the differentiation
nto the myotube (2).
etrovirus-mediated CT-1– gene transfer. The full-length
omplementary deoxyribonucleic acid of the rat CT-1 was
btained from total ribonucleic acid in neonatal rat ven-
ricular cells using reverse transcriptase-polymerase chain
eaction. Sense and antisense primers for rat CT-1 were
-TCTATGAGCCAGAGGGAGGGAAGTCTG-3
nd 5-TATTCAGGCAACGCCCCCTGGCAC-3, re-
pectively (14). The polymerase chain reaction fragment was
onfirmed by deoxyribonucleic acid sequencing and then
Abbreviations and Acronyms
Ang II  angiotensin II
CT-1  cardiotrophin-1
DS  Dahl salt-sensitive
EDD  end-diastolic dimension
ET-1  endothelin-1
%FS  percent fractional shortening
HF  heart failure
LV  left ventricle or left ventricular
MB  transplantation of skeletal myoblasts alone
MB  CT  transplantation of cardiotrophin-1–
expressing myoblasts
PWT  posterior wall thicknessnserted into pLN plasmid (generously provided by Dr. poriyuki Kasahara, USC Institute for Genetic Medicine, Los
ngeles, California) (19) to construct a retroviral transfer
ector encoding the rat CT-1 complementary deoxyribonucleic
cid sequence (pLN-CT-1). Retroviral vector encoding CT-1
as produced as described previously, with slight modifications
19,20). Briefly, a 100-mm dish of nonconfluent 293T cells
ere transfected with 15 g of pLN-CT-1, 15 g of pHIT 60
i.e., cytomegalovirus [CMV] gag pol encoding plasmid), and
0 g pHIT 123 (CMV ecotropic envelope) using the calcium
hosphate coprecipitation method (21); 16 h after transfer, the
edia were adjusted to a final concentration of 10 mM in
odium butyrate. After 8-h incubation, cells were washed and
ncubated in fresh medium without sodium butyrate. Condi-
ioned medium containing retrovirus was harvested 16 h later
nd filtered through 0.45-m Millipore-HA (Millipore Co.,
edford, Massachusetts). For transfer of CT-1 gene into the
yoblasts, cells were infected overnight with a dilution of virus
tock in cultured medium supplemented with 8 g of poly-
rane per ml. Infections were performed twice for efficient
ransfer into myoblasts.
ell transplantation. At the age of 11 weeks, animals
nderwent thoracotomy under general anesthesia with in-
raperitoneal sodium pentobarbital (50 mg/kg) and autolo-
ous transplantation to the myocardium with CT-1-
ransferred myoblasts (MB  CT group, n  31) or
yoblasts alone (MB group, n  31). Cells (1  106) were
arvested and resuspended in 0.15 ml of phosphate-buffered
aline, followed by intramyocardial injection 10 to 15 times
nto the anterior aspects of the LV free wall with a 26G
eedle. Accordingly, approximately 1  105 cells were
njected in each site. In the sham group (n  24), the same
olume of phosphate-buffered saline was injected. The
urgical wounds were repaired, and the rats were returned to
he cages to recover.
chocardiographic and hemodynamic studies. Systolic
lood pressure and heart rate were measured by a tail-cuff
ethod (Muromachi Kikai, Japan).
At the age of 11, 15, and 17 weeks, transthoracic
wo-dimensional echocardiography (SONOS 5500, Philips
edical Systems Corp., Andover, Massachusetts) was per-
ormed under light anesthesia with sodium pentobarbital. A
2-MHz Ultraband Sector Transducer (Philips Medical
ystems Corp.) probe was used. Left ventricular end-
iastolic dimension (EDD), end-systolic dimension (ESD),
nd LV posterior wall thickness (PWT) were determined
rom the M-mode tracing based on the short-axis view of
he LV at the papillary muscle level. Left ventricular percent
ractional shortening (%FS) was calculated as: [(EDD 
SD)/EDD]  100.
At the age of 17 weeks, animals underwent direct cardiac
atheterization via subdiaphragmatic approach to measure
V pressure under light anesthesia. The catheter was
onnected to a pressure transducer, and continuous mea-
urements of LV pressure and heart rate were recorded
sing a Maclab system (Bioresearch Center, Nagoya, Ja-
an). Animals were allowed to breathe spontaneously dur-
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June 16, 2004:2337–47 CT-1–Myoblast Transplantation for HFng the pressure recording. Maximal rate of pressure rise
dP/dtmax) and LV end-diastolic pressure were determined
rom tracings of LV pressure, and averaged on 100 consec-
tive cardiac cycles.
estern blot analysis. At the age of 13 weeks, three hearts
rom each group were collected to assess CT-1 expression in
he heart. The isolated LV free wall was cut into small
ieces and homogenized with a Polytron homogenizer
Kinematica Inc., Cincinnati, Ohio). Homogenates were
entrifuged, and the supernatants were collected. For detec-
ion of secreted CT-1 from the transferred myoblasts,
yoblasts were cultured in DMEM supplemented with
0% FBS, and conditioned media were collected after 72 h
ncubation. The expression of CT-1 protein was determined
y Western blot analysis using an anti-human CT-1 poly-
lonal antibody (Pepro Tech EC Ltd., London, United
ingdom). The results were quantified by scanning
ensitometry.
istological analysis. Left ventricular specimens were ob-
ained at the age of 17 weeks (n  5 for each group).
pecimens were frozen with liquid nitrogen and sectioned
o 8-m-thick slices. The slices were stained with
ematoxylin-eosin. The slices also underwent immunohis-
ochemical staining for skeletal-specific myosin heavy chain
y MY-32 monoclonal antibody (Sigma-Aldrich Inc., St.
ouis, Missouri), and for CT-1.
In the hematoxylin-eosin–stained sections, the cross-
ectional area of cardiac myocytes that was cut transversely
nd showed nuclei in the center was measured in the free
all and the septum of the LV, respectively. In each side of
V wall, approximately 50 cells were counted per each
nimal. Before myoblast transplantation, the myocyte size
as measured at the age of 6 and 11 weeks (n  5 for each
tage). A total of 100 cells in random areas of LV, including
oth the free wall and the septum, were counted per each
nimal, and the average was used for analysis.
easurements of plasma angiotensin II (Ang II) and
ndothelin-1 (ET-1) levels. At the age of 13 and 17
eeks, blood was collected in a polypropylene tube contain-
ng aprotinin (300 kallikrein-inhibiting units/ml) and
thylenediamine-tetraacetic acid (1 mg/ml) and then cen-
rifuged at 3,000 rpm for 15 min at 4°C. The plasma thus
btained was stored at 80°C until assayed. The plasma
evels of Ang II and ET-1 were measured by SRL, Inc.
Tokyo, Japan).
ffects of transferred-gene– derived CT-1 in vitro.
yoblasts were cultured in DMEM supplemented with
.1% bovine serum albumin, ITS (10 g/ml insulin, 10
g/ml transferrin, and 10 ng/ml selenious acid), and con-
itioned media were collected after 72-h incubation. Pri-
ary culture of neonatal rat cardiac myocytes was prepared
s previously described (21). Cardiac myocytes were treated
ith either DMEM supplemented with 0.1% bovine serum
lbumin and ITS (control), the media from myoblasts with
r without CT-1–transfer, or 1 nM recombinant human
T-1 (Pepro Tech EC Ltd.) for 48 h. Then cellular iorphology was examined and photographed under light
icroscopy.
Proliferation and survival tests in myoblasts were per-
ormed by use of C2C12 myoblasts (American Type Cul-
ure Collection, Manassas, Virginia). Briefly, 5,000 cells
ere plated in 96-well dishes and grown for 24-h in media
ontaining 10% FBS. The media were then changed to 0%
r 10% serum-media, and cell number was determined by
he absorbance of the WST-8 reagent (Dojindo Co.,
umamoto, Japan) at 0, 8, 24, and 48 h after media
eplacement.
tatistical procedures. All values were expressed as mean
SEM. The serial measurements of echocardiography
ere assessed using two-way analysis of variance for re-
eated measures. The differences at specific stages among
roups were analyzed by one-way analysis of variance,
ollowed by Bonferroni’s multiple-comparison t test. Paired
test was used to assess significant differences in myocyte
ize between areas in each group. Statistical analyses were
erformed using StatView (version 5.0, SAS Institute Inc.,
ary, North Carolina). Values were considered statistically
ignificant at p  0.05.
ESULTS
unctional assessment after cell transplantation. The
S rats who were fed a high salt diet developed systemic
ypertension (220 mm Hg) at the age of 11 weeks, which
ontinued until the age of 17 weeks. There was no signifi-
ant difference in systolic blood pressure among three
roups throughout the experiment (Table 1). At the age of
4 to 17 weeks, two rats in the sham group and one rat in
he MB group deceased. These animals showed labored
espiration with a loss of activity before they died. There-
ore, the cause of their death seemed to be congestive heart
ailure. At the age of 17 weeks, LV end-diastolic pressure
ncreased, and LV dP/dtmax decreased in the sham group,
eflecting congestive HF (Table 2). In contrast, LV end-
iastolic pressure was not increased, and LV dP/dt was
elatively preserved in both the MB and MB  CT groups.
oreover, LV dP/dtmax was significantly higher in the MB
CT group than in the MB group (p  0.01) (Table 2).
Representative M-mode echocardiograms of the LV at
he papillary muscle level were shown in Figure 1A. At the
ge of 11 weeks, the DS rats developed concentric LV
ypertrophy, and there were no differences in preoperative
ata among the three groups (Fig. 1). At the age of 17
eeks, the sham group showed marked LV dilation and
lobal hypokinesis (Fig. 1A). From the age of 11 to 17
eeks, a marked decrease in %FS and an increase in EDD
ccurred in sham group, which was associated with a
eduction in PWT (%FS, 50.9  0.4 vs. 32.1  1.4; EDD,
.68  0.02 vs. 7.06  0.14 mm; PWT, 2.12  0.05 vs.
.68  0.02 mm) (Fig. 1B). In contrast, LV dilation was
ttenuated, and contractile function was maintained signif-
cantly in both the MB and MB  CT groups at the age of
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CT-1–Myoblast Transplantation for HF June 16, 2004:2337–477 weeks compared with the age-matched sham group (Fig.
). Moreover, %FS, EDD, and PWT were more preserved
n the MB  CT group than in the MB group at the age of
7 weeks (%FS 43.2  0.8 vs. 38.5  1.5; EDD 6.24 
.07 vs. 6.51 0.16 mm; PWT 1.79 0.02 vs. 1.73 0.02
m, p  0.05, respectively) (Fig. 1B). On the other hand,
-mode echocardiogram did not exhibit asymmetrical LV
all motion after cell transplantation in both the MB and
B  CT groups (data not shown).
We also performed Holter electrocardiogram in some
nimals at the age of 17 weeks, which revealed no lethal
rrhythmias after cell transplantation (n  3 in the MB
roup and n  2 in the MB  CT group, data not
hown).
rafted myoblasts in the myocardium. Serial sections of
he transplanted area after cell transplantation were shown
n Figure 2. Graft survival was identified at six weeks after
ransplantation (the age of 17 weeks) by hematoxylin-eosin
taining and immunohistochemical staining for skeletal-
pecific myosin heavy chain, by MY-32 mAb. Multinuclear
longated structure was identified in H-E staining, which
ndicates that myoblasts had differentiated into myotubes
Fig. 2). These muscular structures were positively stained
ith MY-32 (Fig. 2), whereas no cells were stained in the
BS-injected hearts. Positive staining for skeletal myosin
eavy chain revealed the presence of myotubes. Surviving
ells aligned with the cardiac fiber axis within the native
yocardium. On the other hand, accumulation of inflam-
atory cells was hardly detected around the transplanted
rea at day 0 and two weeks, four weeks, and six weeks after
ransplantation in both MB and MB  CT groups. As
eported previously, the fibrosis was found mainly in
Table 1. Systolic Blood Pressure and LVW/BW
n SBP (mm Hg) BW (g)
Sham
11 W 7 214  10 333  6
17 W 3 241  24 337  1
MB
11 W 12 214  8 331  3
17 W 6 221  13 326  1
MB  CT
11 W 11 201  12 329  5
17 W 4 233  20 331  5
Values are presented as mean  SEM.
BW  body weight; CT  cardiotrophin; HW  heart w
systolic blood pressure; W  the age (weeks).
able 2. Hemodynamics at the Age of 17 Weeks
Sham
(n  4)
MB
(n  6)
MB  CT
(n  7)
P/dt max,
mm Hg/s
887.8  85.2 1,252  35† 1,849  168†‡
VEDP, mm Hg 14.0  2.9 6.9  2.3* 6.8  1.1*
alues are presented as mean  SEM. *p  0.05 and †p  0.01 vs. sham group; ‡p
0.01 vs. MB group by ANOVA and Bonferroni’s multiple-comparison t test.
CT  cardiotrophin; dP/dt  maximal dP/dt; LVEDP  Left ventricularmnd-diastolic pressure; MB  myoblasts.erivascular regions of the arterioles (11), and there were no
ifferences in the extent of fibrosis among the three groups.
T-1 expression in the myocardium after cell transplan-
ation. The secretion of transferred gene-derived CT-1
as confirmed in vitro by Western blot analysis (Fig. 3A).
mmunohistochemical staining of the transplanted area for
T-1 is shown in Fig. 3B. Myotubes positively stained for
T-1 were detected in the MB  CT group at six weeks
fter transplantation, whereas no myotubes were stained in
he MB group (Fig. 3B). These data suggest that local
xpression of CT-1 in CT-1–transfected cells was sus-
ained. Positive staining of myocardium for CT-1, although
lightly, was also detected, indicating that endogenous
T-1 was expressed in the myocardium. Western blot
nalysis revealed that tissue expression of CT-1 in the LV
ree wall of the MB  CT group significantly increased
ompared with sham group at two weeks after transplanta-
ion (Fig. 3C) (2.3  0.5-fold, p  0.05).
orphometry of the ventricular myocytes. The cross-
ectional area of LV myocytes markedly increased from the
ge of 6 to 11 weeks (Fig. 4B). Then the sham group
xhibited a slight decrease of myocyte size, although statis-
ically not significant, from the age of 11 to 17 weeks (Fig.
B). In contrast, the myocyte size in both the free wall and
he septum wall of LV increased in the MB  CT group,
rom the age of 11 to 17 weeks (Fig. 4B). At the age of 17
eeks, although no difference in myocyte size was found
etween the sham and MB groups, the myocyte size in the
ree wall was 20% larger in the MB  CT group than in
ham group (p 0.05) (Figs. 4A and 4B). Furthermore, the
yocyte size in the free wall at the cell-injected site was
ignificantly larger than that of septum wall at the remote
ite of cell injection in the MB  CT group at this stage (p
0.05) (Fig. 4B). On the other hand, the myocyte size in
he free wall did not significantly differ from that of the
eptum wall in both the sham and MB groups. We also
emonstrated that the conditioned media from CT-1–
ransferred myoblasts induced cardiac myocyte hypertrophy
n vitro (Fig. 4C). These data suggest that CT-1 secreted
rom grafted cells in the MB  CT group induced hyper-
rophy of the adjacent myocardial cells in a paracrine
tio
HW (mg) LVW (mg) LVW/BW (mg/g)
1,468  83 1,221  69 3.7  0.4
1,514  46 1,199  69 3.7  0.1
1,575  32 1,330  30 4.0  0.1
; LVW  left ventricular weight; MB  myoblasts; SBP Ra
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June 16, 2004:2337–47 CT-1–Myoblast Transplantation for HFeurohumoral regulation during the transition to con-
estive HF. In this DS rat model, it has been demon-
trated that the activation of local renin-angiotensin and
ndothelin systems in the heart contributes to the transition
o heart failure (22,23). Indeed, serum Ang II levels in-
reased at the congestive heart failure stage compared with
he LV hypertrophy stage in sham group (Fig. 5A). How-
ver, these changes were attenuated in both the MB and
B  CT groups, and the degree of attenuation was
reater in MB  CT group than the MB group (p  0.05)
igure 1. (A) Representative tracings of left ventricular M-mode echocard
upper right), the myoblast transplantation (MB) group (lower left), and
ight) at the age of 17 weeks. Left ventricular dilation and contractile dysfu
tage (six weeks after transplantation). (B) Serial measurements of echocardi
f variance: group 0.001; time course 0.001; group/time course interac
0.05, and ††p 0.01 vs. MB group at same stage by Bonferroni’s multip
S  fractional shortening; PWT  posterior wall thickness; W  the aFig. 5A). The serum ET-1 levels were also upregulated euring the transition to congestive heart failure in sham
roup, but remained unchanged in both the MB and MB
T groups (Fig. 5B). We also found that upregulation of
ngiotensinogen, angiotensin-converting enzyme, prepro-
T-1, and ET-converting enzyme messenger ribonucleic
cid in the LV during the transition to congestive heart
ailure were all attenuated by myoblast transplantation,
sing semiquantitative reverse transcriptase-polymerase
hain reaction (data not shown).
he effect of CT-1 on myoblast survival in vitro. To
ms of the sham group at the age of 11 weeks (upper left) and 17 weeks
ransplantation of CT-1–expressing myoblasts (MB  CT) group (lower
n were attenuated in both MB and MB  CT groups at the heart failure
hy in the sham, MB, and MBCT groups. A p value by two-way analysis
0.001 for each parameter. *p  0.05 and **p  0.01 vs. sham group; †p
parison t test. Values are means SEM. EDD end-diastolic diameter;
eeks).iogra
the t
nctio
ograp
tion 
le-com
ge (wxamine the effect of CT-1 on myoblast survival in vitro, we
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CT-1–Myoblast Transplantation for HF June 16, 2004:2337–47sed C2C12 myoblasts rather than rat myoblasts (harvested
rom rats) to avoid contamination of other type cells such as
broblasts. Proliferation rates of cells were measured in 10%
erum-media. Although statistically not significant, the
umber of C2C12 cells transferred CT-1 by retrovirus
C2C12CT-1) tended to be higher than that of parental
2C12 cells at 48 h (Fig. 6A). Then we assessed whether
2C12CT-1 cells were resistant to serum-deprivation-
nduced cell death. In the absence of serum, C2C12 cells
apidly died, whereas C2C12CT-1 cells not only survived but
lso proliferated (Fig. 6B). This protective effect was also
bserved by addition of CT-1 in culture medium (Fig. 6B).
ased on these findings, it is likely that CT-1 augments the
raft survival ratio in the myocardium.
ISCUSSION
n the present study, we examined the effect of skeletal
yoblast transplantation with and without CT-1 gene
ransfer on global heart failure of nonischemic cause.
We demonstrated that the transplantation of skeletal
yoblasts alleviated the transition from compensatory hy-
ertrophy to congestive heart failure in DS hypertensive
ats. So far, only a few animal studies showed that direct
ntramyocardial injection of fetal cardiac myocytes and
mooth muscle cells could improve cardiac function in
lobal heart failure due to nonischemic causes (8–10).
uzuki et al. (24) showed the efficient transplantation of
keletal myoblasts via the intracoronary route to doxorubicin-
nduced HF. Indeed, intracoronary injection is a reasonable
ethod for global dissemination of cells into the heart, but
here might be a danger of myocardial infarction. Intramyo-
ardial injection is the most practical method for cell delivery in
uman patients at the moment. In this study, we injected
keletal myoblasts directly into the myocardium of DS hyper-
igure 2. Serial sections of transplanted area at the age of 17 weeks (six we
ultinuclear elongated structure is typical of myotubes (arrows). Right pan
y MY-32. Positive staining with MY-32 demonstrates the presence of mensive rats at the LV hypertrophy stage (the age of 11 weeks). pix weeks after transplantation, the transplanted myoblasts
urvived and formed myotubes, which aligned with cardiac
ber axis within the native myocardium.
Echocardiographic examination demonstrated reduced
FS, increased EDD, and decreased PWT at the conges-
ive HF stage (the age of 17 weeks) in all groups. Therefore,
entricular dilation and thinning of the ventricular wall were
ssociated with reduced cardiac contractility. Myocardial
uscle fiber slippage and realignment are implicated in the
entricular remodeling of DS hypertensive rats, particularly
n the thinning of the myocardium (25). Myoblast trans-
lantation attenuated these morphologic changes associated
ith ventricular remodeling and served to preserve ventric-
lar function in DS hypertensive rats. Although the precise
echanisms underlying the beneficial effect of myoblast
ransplantation have not been fully elucidated, it is likely
hat their passive girdling effect against mechanical stretch-
ng prevented LV dilation and remodeling (1). In DS
ypertensive rats, activations of local renin-angiotensin or
T systems and matrix metalloproteinases in the heart
ontribute to LV remodeling and contractile dysfunction
uring the transition to heart failure (22,23,25). We found
hat myoblast transplantation attenuated upregulation of
enin-angiotensin and ET systems during the transition to
ongestive HF. Although a causal relationship between the
lteration of these neurohumoral regulations and the func-
ional outcome remains elusive, it is possible that a decrease
n wall stress due to the elastic property of engrafted cells
ttenuated the expression of such neurohumoral factors and
lleviated the LV remodeling. On the other hand, there is a
ossibility that inflammation by direct injection induced
aracrine effects, such as secretion of growth factors, and
mproved the cardiac function (8), but accumulation of
nflammatory cells was hardly detected around the trans-
ter transplantation). Left panel shows hematoxylin-eosin (H-E) staining.
ws immunohistochemical staining for skeletal-specific myosin heavy chain
es (arrows). Original magnification, 400.eks af
el sho
yotublanted area throughout the experiment.
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June 16, 2004:2337–47 CT-1–Myoblast Transplantation for HFActive force generation by grafted cells is another con-
eivable mechanism (1). After engraftment, myoblasts
erge into myotubes, and this graft might contract in
ynchrony with the host tissue. Because gap junction pro-
eins, such as N-cadherin and connexin-43, have been
hown to be downregulated after differentiation into myo-
ubes, the presence of electromechanical coupling seems
nlikely (26,27). On the other hand, simple stretch might
nitiate contraction of myotubes (28).
The efficiency of the cell-mediated gene delivery, which
mploys skeletal myoblasts expressing transforming growth
actor-beta1 or vascular endothelial growth factor, has been
eported (12,13). We examined the effect of prolonged
verexpression of CT-1 in the myocardium by myoblast-
ediated gene transfer using retrovirus.
Cardiotrophin-1 has hypertrophic and cardioprotective
roperties and acts through LIF receptor beta/glycoprotein
igure 3. (A) Detection of secreted cardiotrophin-1 (CT-1) in culture m
nly nonspecific staining was seen in 10% FBS-DMEM and the cond
yoblasts, CT-1 was detected in addition to nonspecific staining. Twice,
tained for CT-1 in the myoblast (MB) group (left) and the MB  CT gro
n the MB  CT group showed positive staining for CT-1 (arrows). O
entricular free wall. Each protein level of CT-1 was normalized to a mea
eans  SEM.30(gp130)-coupledsignalingpathway(14–16).Cardiotrophin- gpromotes cardiac myocyte hypertrophy by directing sar-
omere assembly in series in vitro (15). On the other hand,
T-1 prolongs survival of cardiac myocytes (16,29). Cardiac
yocyte-restricted knockout of gp130 in adult mice devel-
ps LV dilation and induces apoptosis in the myocardium
hen the LV is subjected to increased wall stress, suggesting
hat gp130 signaling has the protective effect on cardiac
yocytes (30). In chronic HF, CT-1 expression in the
yocardium is upregulated corresponding to the severity
17,18). In this study, we demonstrated that the transplan-
ation of skeletal myoblasts expressing CT-1 provides fur-
her benefits in preserving cardiac function compared with
yoblast transplantation alone, suggesting that CT-1 has
he protective effects against ventricular remodeling.
Western blot analysis showed the CT-1 secretion from
T-1–gene transferred myoblasts in vitro and the increased
xpression of CT-1 in the LV free wall of the MB  CT
y Western blot analysis. Human CT-1 was detected as a 26-kDa band.
d media from parental myoblasts. In the media from CT-1-transferred
ions of retrovirus augmented the CT-1 expression. (B) Transplanted area
ight) at the age of 17 weeks (six weeks after transplantation). Grafted cells
al magnification, 400. (C) Western blot analysis for CT-1 in the left
e of sham group (n  5 for each). *p  0.05 vs. sham group. Values areedia b
itione
infect
up (r
rigin
n valuroup in vivo. Immunohistochemical staining exhibited
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CT-1–Myoblast Transplantation for HF June 16, 2004:2337–47hat, in the MB  CT group, overexpression of CT-1 in
rafted cells within myocardium sustained until six weeks
fter transplantation. The plasma level of CT-1 was not
valuated in this study. Intravenous injection of CT-1 has
een reported to elicit systemic hypotension via a nitric
xide-dependent mechanism (31). Because there were no
igure 4. (A) Photomicrographs of cardiac myocytes in the anterior aspect of
center), and MB  cardiotrophin (CT) (right) groups. The bar indicates 50
he free wall (solid bars), and the septum (striped bars) of the LV. Myocyte si
p 0.05 vs. sham group by analysis of variance and Bonferroni’s multiple-com
SEM. (C) Phase-contrast photomicrographs of cultured neonatal rat ventri
he media from parental myoblasts showed no morphologic changes compar
ell hypertrophy, similar to that seen in 1 nM CT-1–incubated CMs. Myoblignificant differences in systolic blood pressure among threeroups throughout the experiment, the plasma level of
T-1 was probably not elevated in the MB  CT group
ompared with the other two groups. We speculate that
ransferred gene-derived CT-1 operated in an autocrine/
aracrine manner at the stage of transition from compen-
ated to decompensated HF.
ntricular (LV) free wall at the age of 17 weeks in sham (left), myoblast (MB)
(B) Relative cross-sectional area of cardiac myocytes in the LV (open bars),
normalized to a mean value of Dahl salt-sensitive rats at the age of six weeks.
on t test. †p 0.05 versus the septum wall by paired t test. Values are means
cardiac myocytes (CM). Cardiac myocytes were treated as described for 48 h.
h control. The media from CT-1–transferred myoblasts induced myocardial
-1  CT-1–transferred myoblasts.left ve
m.
ze was
paris
cular
ed wit
astTransferred gene-derived CT-1 induced myocardial cell
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June 16, 2004:2337–47 CT-1–Myoblast Transplantation for HFypertrophy in vitro, and histological examination revealed
he increased cross-sectional area of myocytes in the MB 
T group in congestive heart failure stage compared with
he MB group. Echocardiographic examination also re-
ealed that the wall thickness was more preserved at the
ongestive HF stage in the MB CT group compared with
igure 5. Plasma levels of angiotensin II (Ang II) (A) and endothelin-1
ET-1) (B) at the age of 13 weeks (open bars) and 17 weeks (solid bars).
alues are means  SEM. n  5 per group. *p  0.05 vs. sham group; †p
0.05 vs. myoblast (MB) group at same stage by analysis of variance and
onferroni’s multiple-comparison t test. CT  cardiotrophin.he MB group. Excessive hypertrophy may induce contrac- tile dysfunction, but the cardiac function of the MB  CT
roup was preserved more effectively than the MB groups.
lthough no definite mechanism has been proven in the
elationship between contractile function and myocardial
ypertrophy, the present findings suggest that CT-1 from
igure 6. Proliferation and survival of parental and cardiotrophin-1 (CT-
)–transferred myoblasts in media containing 10% (A) or 0% (B) serum.
ell number was determined by the absorbance of the WST-8 reagent.
ptical density values were normalized to the mean value of each group at
h. Data are presented as mean  SEM of four measurements. *p  0.05
nd **p  0.01 vs. parental C2C12 cells at same time point by analysis of
ariance and Bonferroni’s multiple-comparison t test. C2C12CT-1 
T-1–transferred C2C12 cells.he transplanted cells serves to maintain cardiac function by
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CT-1–Myoblast Transplantation for HF June 16, 2004:2337–47nducing hypertrophy of the adjacent cardiac myocytes.
ardiotrophin-1 is known to be a survival factor for cardiac
yocytes (16). In the present study, we revealed that CT-1
lso has a survival effect on myoblast in vitro. Therefore, it
s also possible that CT-1 augmented the graft survival ratio
n the myocardium and, thus, enhanced the beneficial effects
f cell transplantation. To elucidate this issue, quantitative
ssessment of the area of injected myoblasts is needed. Also,
t is important to verify that myoblasts were injected to the
quivalent extent of areas between rats in the MB group and
hose in the MBCT group. We tried to measure the graft
urvival ratio by use of a retroviral vector encoding CT-1–
RES (internal ribosomal entry site)-green fluorescent pro-
ein gene; however, the system did not work in the trans-
lanted hearts. Those are the limitations of the present
tudy, and recently reported new methods may help to
esolve this issue (32,33).
In conclusion, we demonstrated that MB myoblasts
lleviated the transition from compensatory hypertrophy to
ongestive heart failure in DS hypertensive rats. Transplan-
ation of CT-1–expressing skeletal myoblasts by retroviral-
ediated gene transfer resulted in prolonged overexpression
f CT-1 within myocardium and preserved cardiac function
ore effectively. The results of this study suggest that CT-1
as the protective effects against ventricular remodeling.
ransplantation of skeletal myoblasts combined with CT-
–gene transfer could be a useful strategy for the treatment
f HF.
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